Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H2 2017
Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H2 2017
SUMMARY
Somatostatin Receptor Type 4 (SSTR4) - Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene. The activity of receptor is mediated by G proteins which inhibits adenylyl cyclase. It mediates antiproliferative action of somatostatin in tumor cells. It is functionally coupled to inhibition of adenylate cyclase and activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade.
Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I and Discovery stages are 1, 1 and 3 respectively. Report covers products from therapy areas Central Nervous System, Hormonal Disorders, Metabolic Disorders and Oncology which include indications Chronic Pain, Neuropathic Pain, Acromegaly, Diabetic Retinopathy, Gastrointestinal Tumor, Inflammatory Pain, Neuroendocrine Tumors, Pancreatic Tumor and Pituitary ACTH Hypersecretion (Cushing Disease).
The latest report Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H2 2017, outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Somatostatin Receptor Type 4 (SSTR4) - Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene. The activity of receptor is mediated by G proteins which inhibits adenylyl cyclase. It mediates antiproliferative action of somatostatin in tumor cells. It is functionally coupled to inhibition of adenylate cyclase and activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade.
Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I and Discovery stages are 1, 1 and 3 respectively. Report covers products from therapy areas Central Nervous System, Hormonal Disorders, Metabolic Disorders and Oncology which include indications Chronic Pain, Neuropathic Pain, Acromegaly, Diabetic Retinopathy, Gastrointestinal Tumor, Inflammatory Pain, Neuroendocrine Tumors, Pancreatic Tumor and Pituitary ACTH Hypersecretion (Cushing Disease).
The latest report Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H2 2017, outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 4 (SSTR4)
- The report reviews Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 4 (SSTR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 4 (SSTR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Somatostatin Receptor Type 4 (SSTR4) - Overview
Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 4 (SSTR4) - Companies Involved in Therapeutics Development
Centrexion Therapeutics Corp
Crinetics Pharmaceuticals Inc
Strongbridge Biopharma plc
Somatostatin Receptor Type 4 (SSTR4) - Drug Profiles
CNTX-0290 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somatostatin Receptor Type 4 (SSTR4) - Dormant Products
Somatostatin Receptor Type 4 (SSTR4) - Product Development Milestones
Featured News & Press Releases
Jul 18, 2017: Centrexion Provides Pipeline Updates, Plans for Phase 2 Study of Pain Drug Candidate CNTX-0290
May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
Apr 27, 2015: Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain
Apr 22, 2014: Aspireo Reports Data in Further Phase Ib Study
Sep 25, 2013: FDA Grants Orphan Drug Designation for Aspireo’s Somatoprim
Jun 18, 2013: Aspireo Reports Start of Further Phase I Study in Healthy Volunteers
Apr 03, 2013: Aspireo Pharma Reports Somatoprim Phase IIa Proof Of Concept Results In Acromegaly
Jan 07, 2013: Aspireo Pharma Reports Phase Ib Interim Data For Somatoprim
Nov 26, 2012: Aspireo Pharma Announces EMA's Committee For Orphan Medicinal Products Recommends Orphan Medicinal Product Designation For Somatoprim
Nov 06, 2012: Aspireo Pharma Starts Somatoprim Phase IIa Study In Acromegaly Patients
Sep 28, 2012: Evotec And Aspireo Pharma Enter Into Strategic Advisory Agreement For Somatoprim
Jun 26, 2012: Somatoprim is a potent agonist of Somatostatin Receptors 2 and
Apr 05, 2012: Aspireo Starts Phase I Multi Ascending Dose Study with Somatoprim
Feb 26, 2009: DeveloGen Reports Positive Phase I Clinical Trial Results for DG3173
Oct 08, 2008: DeveloGen Announces Completion Of A Phase I Clinical Trial Of DG3173, A Novel Somatostatin Analogue For The Treatment Of Acromegaly
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Somatostatin Receptor Type 4 (SSTR4) - Overview
Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 4 (SSTR4) - Companies Involved in Therapeutics Development
Centrexion Therapeutics Corp
Crinetics Pharmaceuticals Inc
Strongbridge Biopharma plc
Somatostatin Receptor Type 4 (SSTR4) - Drug Profiles
CNTX-0290 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somatostatin Receptor Type 4 (SSTR4) - Dormant Products
Somatostatin Receptor Type 4 (SSTR4) - Product Development Milestones
Featured News & Press Releases
Jul 18, 2017: Centrexion Provides Pipeline Updates, Plans for Phase 2 Study of Pain Drug Candidate CNTX-0290
May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
Apr 27, 2015: Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain
Apr 22, 2014: Aspireo Reports Data in Further Phase Ib Study
Sep 25, 2013: FDA Grants Orphan Drug Designation for Aspireo’s Somatoprim
Jun 18, 2013: Aspireo Reports Start of Further Phase I Study in Healthy Volunteers
Apr 03, 2013: Aspireo Pharma Reports Somatoprim Phase IIa Proof Of Concept Results In Acromegaly
Jan 07, 2013: Aspireo Pharma Reports Phase Ib Interim Data For Somatoprim
Nov 26, 2012: Aspireo Pharma Announces EMA's Committee For Orphan Medicinal Products Recommends Orphan Medicinal Product Designation For Somatoprim
Nov 06, 2012: Aspireo Pharma Starts Somatoprim Phase IIa Study In Acromegaly Patients
Sep 28, 2012: Evotec And Aspireo Pharma Enter Into Strategic Advisory Agreement For Somatoprim
Jun 26, 2012: Somatoprim is a potent agonist of Somatostatin Receptors 2 and
Apr 05, 2012: Aspireo Starts Phase I Multi Ascending Dose Study with Somatoprim
Feb 26, 2009: DeveloGen Reports Positive Phase I Clinical Trial Results for DG3173
Oct 08, 2008: DeveloGen Announces Completion Of A Phase I Clinical Trial Of DG3173, A Novel Somatostatin Analogue For The Treatment Of Acromegaly
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Centrexion Therapeutics Corp, H2 2017
Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
Pipeline by Strongbridge Biopharma plc, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Dormant Products, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Centrexion Therapeutics Corp, H2 2017
Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
Pipeline by Strongbridge Biopharma plc, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Dormant Products, H2 2017 (Contd.2), H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Centrexion Therapeutics Corp
Crinetics Pharmaceuticals Inc
Strongbridge Biopharma plc
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Centrexion Therapeutics Corp
Crinetics Pharmaceuticals Inc
Strongbridge Biopharma plc
